ADC Therapeutics SA (ADCT)
NYSE: ADCT · Real-Time Price · USD
3.090
+0.150 (5.10%)
At close: Aug 13, 2025, 4:00 PM
3.090
0.00 (0.00%)
After-hours: Aug 13, 2025, 7:00 PM EDT
ADC Therapeutics Revenue
ADC Therapeutics had revenue of $18.84M in the quarter ending June 30, 2025, with 8.21% growth. This brings the company's revenue in the last twelve months to $77.25M, up 15.73% year-over-year. In the year 2024, ADC Therapeutics had annual revenue of $70.84M with 1.84% growth.
Revenue (ttm)
$77.25M
Revenue Growth
+15.73%
P/S Ratio
4.31
Revenue / Employee
$291,494
Employees
265
Market Cap
347.62M
Revenue Chart
Revenue History
Sources: Historical revenue is based on company filings submitted to the U.S. Securities and Exchange Commission (SEC). The most recent revenue numbers may be taken from company press releases.
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
Company Name | Revenue |
---|---|
UnitedHealth Group | 422.82B |
Johnson & Johnson | 90.63B |
Merck & Co. | 63.62B |
AbbVie | 58.33B |
AstraZeneca | 56.50B |
Novartis AG | 55.19B |
Eli Lilly and Company | 53.26B |
Novo Nordisk | 49.11B |
ADCT News
- 1 day ago - ADC Therapeutics SA (ADCT) Q2 2025 Earnings Call Transcript - Seeking Alpha
- 1 day ago - ADC Therapeutics Reports Second Quarter 2025 Financial Results and Provides Operational Update - PRNewsWire
- 8 days ago - ADC Therapeutics to Host Second Quarter 2025 Financial Results Conference Call on August 12, 2025 - PRNewsWire
- 12 days ago - ADC Therapeutics Makes Grants to New Employees Under Inducement Plan - PRNewsWire
- 6 weeks ago - ADC Therapeutics Makes Grant to New Employee Under Inducement Plan - PRNewsWire
- 2 months ago - ADC Therapeutics Announces Updated ZYNLONTA® Investigator-Initiated Trial Data in R/R Marginal Zone Lymphoma Presented at 18th International Conference on Malignant Lymphoma (ICML) - PRNewsWire
- 2 months ago - ADC Therapeutics Announces $100 Million Private Placement Extending Expected Cash Runway into 2028 - PRNewsWire
- 2 months ago - ADC Therapeutics Announces Updated Data from LOTIS-7 Clinical Trial Presented at the European Hematology Association 2025 Congress - PRNewsWire